Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-δ agonist treatment

J Gastroenterol Hepatol. 2013 Jan;28(1):179-87. doi: 10.1111/j.1440-1746.2012.07256.x.

Abstract

Background and aim: Chronic alcoholic liver disease is associated with hepatic insulin resistance, dysregulated lipid metabolism with increased toxic lipid (ceramide) accumulation, lipid peroxidation, and oxidative and endoplasmic reticulum (ER) stress. Peroxisome-proliferator activated receptor (PPAR) agonists are insulin sensitizers that can restore hepatic insulin responsiveness in both alcohol and non-alcohol-related steatohepatitis. Herein, we demonstrate that treatment with a PPAR-δ agonist enhances insulin signaling and reduces the severities of ER stress and ceramide accumulation in an experimental model of ethanol-induced steatohepatitis.

Methods: Adult male Long Evans rats were pair fed with isocaloric liquid diets containing 0% or 37% ethanol (caloric) for 8 weeks. After 3 weeks on the diets, rats were treated with vehicle or PPAR-δ agonist twice weekly by i.p. injection.

Results: Ethanol-fed rats developed steatohepatitis with inhibition of signaling through the insulin and insulin-like growth factor-1 receptors, and Akt activated pathways. Despite continued ethanol exposure, PPAR-δ agonist co-treatments increased Akt activation, reduced multiple molecular indices of ER stress and steatohepatitis.

Conclusions: These results suggest that PPAR-δ agonist rescue of chronic alcoholic liver disease is mediated by enhancement of insulin signaling through Akt/metabolic pathways that reduce lipotoxicity and ER stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Ceramides / metabolism
  • Endoplasmic Reticulum / drug effects*
  • Endoplasmic Reticulum / physiology
  • Endoplasmic Reticulum / ultrastructure*
  • Fatty Liver, Alcoholic / drug therapy
  • Fatty Liver, Alcoholic / metabolism
  • Fatty Liver, Alcoholic / physiopathology*
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Resistance*
  • Male
  • PPAR delta / agonists*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Long-Evans
  • Receptor, IGF Type 1 / metabolism
  • Receptor, Insulin / metabolism
  • Signal Transduction / drug effects
  • Stress, Physiological / drug effects*

Substances

  • Ceramides
  • Insulin Receptor Substrate Proteins
  • PPAR delta
  • Receptor, IGF Type 1
  • Receptor, Insulin
  • Proto-Oncogene Proteins c-akt